MDCX

Company Overview — What Does Medicus Pharma Ltd. Do?

Medicus Pharma Ltd. is a clinical-stage pharmaceutical company focused on developing and commercializing innovative therapies for unmet medical needs, with an initial focus on dermatological conditions. They are developing a novel microneedle patch technology for targeted drug delivery. Medicus Pharma Ltd. (MDCX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Raza Bokhari, headquartered in W. CONSHOHOCKEN, Pennsylvania. With a market capitalization of $12M, MDCX is one of the notable companies in the Healthcare sector.

Medicus Pharma Ltd. (MDCX) Stock Rating — Avoid (April 2026)

As of April 2026, Medicus Pharma Ltd. receives a Avoid rating with a composite score of 21.4/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.MDCX ranks #4,425 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Medicus Pharma Ltd. ranks #835 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

MDCX Stock Price and 52-Week Range

Medicus Pharma Ltd. (MDCX) currently trades at $0.44. The stock lost $0.00 (0.2%) in the most recent trading session. The 52-week high for MDCX is $8.94, which means the stock is currently trading -95.1% from its annual peak. The 52-week low is $0.37, putting the stock 19.2% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is MDCX Overvalued or Undervalued? — Valuation Analysis

Medicus Pharma Ltd. (MDCX) carries a value factor score of 8/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 474.74x, versus the sector average of 2.75x. The price-to-sales ratio is 245.90x, compared to 1.66x for the average Healthcare stock.

At current multiples, Medicus Pharma Ltd. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Medicus Pharma Ltd. Profitability — ROE, Margins, and Quality Score

Medicus Pharma Ltd. (MDCX) earns a quality factor score of 21/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -379988.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -1409.1% versus the sector average of -33.1%.

The operating margin is -0.1% (sector: -66.1%). Net profit margin stands at -138103.3%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

MDCX Debt, Balance Sheet, and Financial Health

Medicus Pharma Ltd. has a debt-to-equity ratio of 26866.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.00x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $7M. Cash and equivalents stand at $9M.

MDCX has a beta of 0.67, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Medicus Pharma Ltd. is 25/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Medicus Pharma Ltd. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Medicus Pharma Ltd. reported revenue of $-197,382 and earnings per share (EPS) of $-2.74. Net income for the quarter was $-35M. Operating income came in at $-34M.

In FY 2025, Medicus Pharma Ltd. reported revenue of $-197,382 and earnings per share (EPS) of $-2.74. Net income for the quarter was $-35M. Operating income came in at $-34M.

In Q3 2025, Medicus Pharma Ltd. reported revenue of $11,572 and earnings per share (EPS) of $-1.12. Net income for the quarter was $-16M. Operating income came in at $-15.

In Q2 2025, Medicus Pharma Ltd. reported revenue of $40,004 and earnings per share (EPS) of $-0.43. Net income for the quarter was $-6M. Operating income came in at $-6M.

Over the past 7 quarters, Medicus Pharma Ltd. has experienced revenue contraction from $0 to $-197,382. Investors analyzing MDCX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

MDCX Dividend Yield and Income Analysis

Medicus Pharma Ltd. (MDCX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

MDCX Momentum and Technical Analysis Profile

Medicus Pharma Ltd. (MDCX) has a momentum factor score of 9/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 65/100 reflects moderate short selling activity.

MDCX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Medicus Pharma Ltd. (MDCX) ranks #835 out of 838 stocks based on the Blank Capital composite score. This places MDCX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing MDCX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MDCX vs S&P 500 (SPY) comparison to assess how Medicus Pharma Ltd. stacks up against the broader market across all factor dimensions.

MDCX Next Earnings Date

No upcoming earnings date has been announced for Medicus Pharma Ltd. (MDCX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy MDCX? — Investment Thesis Summary

The quantitative profile for Medicus Pharma Ltd. suggests caution. The quality score of 21/100 flags below-average profitability. The value score of 8/100 indicates premium valuation. Momentum is weak at 9/100, a headwind for near-term performance. High volatility (stability score 25/100) increases portfolio risk.

In summary, Medicus Pharma Ltd. (MDCX) earns a Avoid rating with a composite score of 21.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MDCX stock.

Related Resources for MDCX Investors

Explore more research and tools: MDCX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MDCX head-to-head with peers: MDCX vs AZN, MDCX vs SLGL, MDCX vs VMD.